key: cord-0807562-fgnpz11i authors: Mukhtar, Amnah; Shukry, Murooj; Bannan, Douha title: Safe handling and delivery of biological medications during the COVID‐19 pandemic date: 2021-03-18 journal: J Clin Pharm Ther DOI: 10.1111/jcpt.13399 sha: b460cd133d8d5d7d82b0128fff6c7a8119fb5a3d doc_id: 807562 cord_uid: fgnpz11i WHAT IS KNOWN AND OBJECTIVE: During the coronavirus disease of 2019 (COVID‐19) pandemic, there were periods when patients were not able to collect their medications from the hospital. The purpose of this study is to report on our management of the handling and delivery of biological medications to patients during periods of lockdown in the Kingdom of Saudi Arabia (KSA). METHODS: A descriptive study conducted at our 380‐bed tertiary care hospital. Managing the delivery of the biological medications was organized in six phases: (1) taskforce development, (2) identification of the relevant biological medications, (3) identification of patients, (4) organization of transportation, (5) medication delivery/pickup and (6) locating patients with unidentified addresses. The study was approved by our hospital's Institutional Review Board. RESULTS AND DISCUSSION: Biological medications were delivered to 1235/1373 (90%) patients. This included 1875/2036 (92%) prescriptions. 900 prescriptions were delivered to 570 patients living in 95 cities and villages across the kingdom. 141 patients received 183 prescribed oral biological medications and 477 patients received 787 prescribed parenteral biological medications delivered with temperature control. 224 parenteral biological medication were delivered by car to 116 patients living in less accessible cities in the west of the country. The car deliveries of parenteral biological medications required particularly careful handling, packaging and temperature control. Delivering biological medications to patients during the curfew was a unique experience. However, the approach we have used ensured safe access to medications under appropriate conditions. WHAT IS NEW AND CONCLUSION: Delivering biological medications to patients during the lockdown was challenging. With the possibility of a second wave of COVID‐19, hospitals should have a standardized process in‐place for delivering such medications. A biological medication is "a substance that is made from a living organism or its products." 1 Biological medications such as antibodies, interleukins, blood components and vaccines are used in the prevention and treatment of a variety of conditions such as diabetes, heart attacks, autoimmune disorders and cancer. Biological medications differ from conventional medications, as they are complex mixtures that are susceptible to thermal stress and can be easily affected by excessive shaking. Therefore, they should be carefully transported and stored to prevent spoiling. 2 Some oral and parenteral biologic medications are defined as hazardous per their risk of occupational exposure and require special handling, storage, preparation and administration precautions. 3 Some oral biological medications may not pose a significant risk of direct occupational exposure because of their dosage formulation (eg coated tablets or capsules-solid, intact medications that are administered to patients without modification of the formulation). Dispensing a single tablet to a patient may pose a relatively low risk to a healthcare worker who uses a single pair of gloves. Parenteral medications are normally given in a hospital, and special considerations are taken to ensure safe handling of these medications. However, some of these medications can also be given subcutaneously via self-injection at home because they are dispensed in a ready-to-use form (eg prefilled injection). If given at home, a healthcare personnel specializing in home treatments would deliver the medication to the patient and make sure the patient knows how to self-administer it. In an effort to control the spread of COVID-19 infection, the Kingdom of Saudi Arabia (KSA) enforced a very restricted curfew. During that curfew, there were periods when patients were not able to collect their medications from the hospital pharmacy as usual. Therefore, the pharmaceutical care division in our institution developed a taskforce to ensure patients were able to receive their medications quickly and safely. The purpose of this study is to report on our management of the handling and delivery of biological medications to patients during periods of lockdown in the KSA. This is a descriptive study conducted at our 380-bed tertiary care hospital in Jeddah, KSA between March and June of 2020. The main aim of this paper is to describe the processes implemented by the pharmaceutical care division to deliver biological medications to patients' homes during the COVID-19 curfew quickly, safely and effectively. The process and timeline for handling and delivering biological medications are listed in Table 1 . Initially, the taskforce collected data from the available resources. Recommendations for special handling and packaging requirements were based on the National Institute for Occupational Safety and Health (NIOSH) as well as medication package inserts from manufacturers. For example, parenteral biological medications that should not be shaken were packed in plastic bubble wrap to minimize shaking. If they required special temperature control, they were transported in ice-packed containers with temperature loggers. The handling and packaging precautions for oral biological medications were limited to being dispensed in biohazard plastic bags if classified as biohazards per NIOSH, 3 so those medications were eligible for shipping through mail. Interestingly, some parenteral biological medications were considered stable enough to be mailed with minimum handling and packaging instructions (temperature control) based on the medication package inserts (Appendix B). To focus the effort on patients in need of biological medications, only patients who had received biological medications within the last 3 months were included in the study. Reconciling patient contact and address information required a lot of effort and time. Attention was focused on patients with active prescriptions first to enable quick dispensation of their medications. This is because many patients on the list did not have active prescriptions and/or required medical evaluation by their primary care physicians, who were referred to them for assessment and prescription updates as appropriate. Additionally, multiple options were explored to support delivering biological medications to patients' homes safely: (1) Develop an agreement with the hospital nearest to a patient to be a dispensing site. All medications will be car-delivered to the hospital in readyto-dispense bags. Patients will present their electronic prescriptions from electronic medical records to pick up the medications. (2) Contract with a mail courier that follows special handling and packaging requirements for parenteral biological medications. If patients could not pick up their medications, they were mailed. In our efforts to deliver medications to patients, recommendations for special handling and packaging requirements were based on the NIOSH 3 and medication package inserts from manufacturers. With the possibility of a second wave of COVID-19, hospitals should have a standardized process in-place for delivering such medications. This might be possible by establishing national guidelines for safe handling and delivery of medications through mail by air or car. In addition, having practices that hospitals can adopt might also help standardize the process between hospitals. Patients used to pick up their medications from hospitals. Therefore, the pharmacists' major role was ensuring the safe We successfully delivered 2036 medications to 1373 patients in the west of the country during the curfew. This is an achievement, given the situation in question. However, we did not assess the challenges faced by the people delivering these medications and ways to F I G U R E 2 Top 20 delivered oral biological medications Dispensing method Car delivery 1 Mail order 462 Close follow-up with mail couriers for each patient to ensure the receipt of medications was essential. Many lessons were learned from conducting this study, and the following recommendations may make the handling and delivering of biological medications easier, safer and more effective: -Prepare a list of patients on special medications from the hospital's information system for easy access when needed. -Update and correct patients' contact numbers and addresses in the electronic medical records to ensure that staff can communicate with patients and deliver services in an efficient and timely manner. -Provide special training to pharmacy staff with evidence-based references on handling and packaging special medications in the formulary that require specific handling instructions; apply safety and monitoring measures to ensure implementation of the recommendations. -Ensure availability of supplies for special packing and monitoring materials, such as bubble wrap, ice packs and temperature loggers in the ambulatory care pharmacy to be used when special medication handling and packaging are desired. -Establish a contract with medication carrier that specializes in medication delivery and has the ability to maintain the medications' stability and apply special handling precautions, especially for biological medications. -Request and monitor availability of special packing and monitoring materials at all times in the ambulatory care pharmacy. -Initiate collaborative agreements with treating physicians to ensure continuity of care for this patient population and the active validity of prescriptions. -Contract with mail and car delivery couriers that can guarantee appropriate handling of all medications, including temperatureand shaking-sensitive medications, that comply with national and international medication safety standards and best practices. Delivering biological medications to patients during the lockdown was challenging. With the possibility of a second wave of COVID-19, hospitals should have a standardized process in-place for delivering such medications. We No conflicts of interest have been declared. The data that support the finding of this study are available from What are "biologics" questions and answers NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings CFR -Code of Federal regulations Title 21 The International Air Transport Association. Pharma and healthcare products handling Xalkori (crizotinib) Sprycel (dasatinib) Bristol-Myers Squibb Company Ferring Pharmaceuticals Inc Novartis Pharma Stein AG Research Triangle Park, NC: GlaxoSmithKline Jakafi (ruxolitinib) Incyte Corporation Research Triangle Park, NC: GlaxoSmithKline Summit, NY: Celgene Corporation Exela Pharma Sciences Research Triangle Park, NC: GlaxoSmithKline Humalog mix50/50 (50% insulin lispro protamine) Novo Nordisk Menopur (menotropins) Novo Nordisk Novo Nordisk NovoLog Mix 70/30 (70% insulin aspart protamine and 30% insulin aspart injection Novo Nordisk Novo Nordisk Production SAS Abbot Laboratories Kadcyla (ado-trastuzumab emtansine) Kineret (anakinra) Swedish Orphan Biovitrum AB Recombinate (antihemophilic factor) CA: Baxter Healthcare Corporation Ilaris (canakinumab) Dupixent (dupilumab) Regeneron Pharmaceuticals Inc CA: Immunex Corporation Repatha (evolocumab) NovoSeven (coagulation factor VIIa (Recombinant)) Novo Nordisk CSL Behring GmbH CSL Behring GmbH Avonex (interferon beta-1a) Biogen Idec Pegasys (peginterferon alfa-2a) Schering Corporation Cosentyx (secukinumab) NJ: Novartis Pharmaceuticals Corporation Actemra (tocilizumab) Exela Pharma Sciences LLC Herceptin (trastuzumab) Stelara (ustekinumab) How to cite this article: Mukhtar A, Shukry M, Bannan D. Safe handling and delivery of biological medications during the COVID-19 pandemic ML BTL Nasal spray: store at 20°C to 25°C (68°F to 77°F). Keep nasal spray in upright position Refrigerate (2-8 degrees C), do not freeze, protect from light and store in original container 000) Store in refrigerator at 2°C to 8°C in the original package. Do not freeze or shake. Protect from light. Discard any unused portion ETANERCEPT INJ 25 MG (PRE-FILLED SYRINGE) Refrigerate (2-8 degrees C), do not freeze, protect from light and store in original container ETANERCEPT INJ 50 MG (MYCLIC) Refrigerate (2-8 degrees C), do not freeze Avoid exposure to direct sunlight FACTOR VIII AND VON WILLEBRAND (HUMAN) INJ 500 IU VIAL (HAEMATE P 500®) Store up to 25°C. Avoid freezing FACTOR XIII CONCENTRATE (HUMAN) 250 IU, 1250 IU POWDER FOR INJECTION, 20 ML VIAL Store at 2°C to 8°C; do not freeze. Protect from light. May be stored at room temperature max of 25°C for up to 6 months FILGRASTIM (GCSF) INJ 30 MU (300 MCG/ML) 1 ML VIAL Store in refrigerator at 2°C to 8°C in the carton. Do not freeze or shake. Protect from direct sunlight. Discard any unused portion FILGRASTIM (AAFI) Discard any unused portion INHIBITOR C1 ESTERASE (HUMAN), POWDER FOR INJECTION 500 UNIT/VIAL Store intact vials at 2°C to 30°; do not freeze. Store in original carton; protect from light. Use within 8 hours of reconstitution (Canadian labelling recommends immediate use after reconstitution); do not refrigerate or freeze reconstituted solution. Discard any unused product INTERFERON BETA −1A INJ, 30 MCG/ 0.5 ML PRE-FILLED PEN (AVONEX®) Store Protect from heat and light INTERFERON BETA −1A SOLUTION FOR INJECTION 44 MCG, 132 MCG/1.5 ML CARTRIDGE (MULTI DOSE REBIF® Store at 2°C to 8°C; do not freeze MIU/0.5ML(PRE-FILLED SYRINGE) (REBIF−44®) Protect from heat and light PEGFILGRASTIM 10 MG/ML (0.6 ML) PRE-FILLED SYRINGE Store at 2°C to 8°C; do not freeze or shake. Protect from sunlight PEGINTERFERON ALFA−2A 135 MCG Discard any unused portion PEGINTERFERON ALFA−2B 50 MCG/0.5 ML PEN (PEG-INTRON®) Prior to reconstitution, store Redipen at 2°C to 8°C. Do not freeze RITUXIMAB INJ 10 MG/ML 10 ML VIAL Refrigerate (2-8 degrees C), do not freeze, protect from light and store in original container RITUXIMAB SOLUTION FOR SC INJECTION 1400/11.7 ML, VIAL (MABTHERA) Store in a refrigerator (2°C-8°C). Keep the container in the outer carton in order to protect from light ROMIPLOSTIM POWDER FOR SOLUTION FOR INJECTION 250 MCG VIAL Store at 2°C to 8°C Store intact vials, Sensoready pens and prefilled syringes refrigerated at 2°C to 8°C (36°F to 46°F) do not freeze, protect from light and store in original container TOCILIZUMAB SOLUTION FOR SUBCUTANEOUS INJ 162 MG/0.9 ML, 1ML PREFILLED SYRINGE Sensoready pens, prefilled syringes and vials must be refrigerated at 2oC to 8oC (36oF to 46oF)